New ublituximab data in multiple sclerosis to be presented at ECTRIMS Congress 2025 alongside partner TG Therapeutics

Barcelona, Spain and Düsseldorf, Germany – 22 September, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces its participation at 41^st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Annual Congress, taking place in Barcelona from 24–26 September.

Together with partner, TG Therapeutics, Neuraxpharm will present new data for BRIUMVI^® (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS) at a series of sessions, for healthcare professionals and researchers committed to shaping the future of MS care. Neuraxpharm will also host a dedicated booth (#Stand04) which will feature exclusive Booth Talks led by renowned MS experts and explore the role of this medicine in the treatment landscape.

Details of the upcoming presentations are outlined below.

Presentations:

Oral Presentation: Long-term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from Six Years of ULTIMATE I and II Open-label Extension

·         Session: Free Communication 2: Therapeutic interventions - from trials to real-world evidence

·         Date/Time: Wednesday, September 24 at 14:55–15:05 CEST (08:55–09:05 ET)

·         Location: Lecture Hall 117

·         Abstract Number: ECTRIMS25-1571

·         Lead Author: Dr. Bruce Cree - Weill Institute for Neurosciences, University of California, San Francisco, CA, United States

ePoster Presentation: Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE Study

·         Date/Time: ePoster will be made available on ECTRIMS platform beginning Wednesday 24 September (accessible for three months post-congress)

·         Abstract Number/ePoster Number: ECTRIMS25-1575/P1699

·         Lead Author: Barry A. Singer, MD - Director, The MS Center for Innovations in Care - Missouri Baptist Medical Center, St. Louis, MO, United States

ePoster Presentation: Real-World Clinical Experience from ENABLE: the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab

·         Date/Time: ePoster will be made available on ECTRIMS platform beginning Wednesday 24 September (accessible for three months post-congress)

·         Abstract Number/ePoster Number: ECTRIMS25-1597/P1833

·         Lead Author: Dr. Carrie Hersh, DO - Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, United States

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: “A key pillar of Neuraxpharm’s growth strategy is to continue strengthening our position as a CNS specialist, offering differentiated products to patients and healthcare professionals across Europe and beyond. Participating in ECTRIMS reflects our dedication to advancing MS care and our ambition to expand access to innovative therapies.”